As of 2025-11-08, the EV/EBITDA ratio of Ligand Pharmaceuticals Inc (LGND) is -38,244.74. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LGND's latest enterprise value is 3,900.96 mil USD. LGND's TTM EBITDA according to its financial statements is -0.10 mil USD. Dividing these 2 quantities gives us the above LGND EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 10.3x - 14.0x | 12.1x |
| Forward P/E multiples | 11.0x - 18.5x | 13.8x |
| Fair Price | 3.39 - 3.38 | 3.38 |
| Upside | -98.3% - -98.3% | -98.3% |
| Date | EV/EBITDA |
| 2025-11-07 | -38,244.74 |
| 2025-11-06 | -39,347.72 |
| 2025-11-05 | -35,919.64 |
| 2025-11-04 | -35,740.93 |
| 2025-11-03 | -36,084.89 |
| 2025-10-31 | -36,098.34 |
| 2025-10-30 | -35,281.68 |
| 2025-10-29 | -34,793.60 |
| 2025-10-28 | -35,629.48 |
| 2025-10-27 | -35,840.85 |
| 2025-10-24 | -35,266.30 |
| 2025-10-23 | -34,933.87 |
| 2025-10-22 | -34,995.36 |
| 2025-10-21 | -35,204.81 |
| 2025-10-20 | -35,220.19 |
| 2025-10-17 | -34,242.11 |
| 2025-10-16 | -34,073.01 |
| 2025-10-15 | -34,559.17 |
| 2025-10-14 | -34,101.83 |
| 2025-10-13 | -33,903.91 |
| 2025-10-10 | -33,488.85 |
| 2025-10-09 | -34,370.85 |
| 2025-10-08 | -34,787.83 |
| 2025-10-07 | -34,532.26 |
| 2025-10-06 | -34,426.58 |
| 2025-10-03 | -34,115.28 |
| 2025-10-02 | -33,948.11 |
| 2025-10-01 | -33,747.30 |
| 2025-09-30 | -33,375.48 |
| 2025-09-29 | -32,604.93 |
| 2025-09-26 | -31,949.68 |
| 2025-09-25 | -31,380.89 |
| 2025-09-24 | -31,803.64 |
| 2025-09-23 | -32,128.38 |
| 2025-09-22 | -32,151.44 |
| 2025-09-19 | -31,332.85 |
| 2025-09-18 | -31,970.81 |
| 2025-09-17 | -31,121.48 |
| 2025-09-16 | -31,280.97 |
| 2025-09-15 | -31,141.66 |
| 2025-09-12 | -31,186.81 |
| 2025-09-11 | -31,438.54 |
| 2025-09-10 | -31,229.09 |
| 2025-09-09 | -31,120.52 |
| 2025-09-08 | -31,207.95 |
| 2025-09-05 | -31,378.97 |
| 2025-09-04 | -31,569.21 |
| 2025-09-03 | -31,338.62 |
| 2025-09-02 | -30,798.66 |
| 2025-08-29 | -30,410.50 |